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Abstract Asialo-transferrin from human cerebrospinal fluid 
was purified to homogeneity. Investigation of the structural char- 
acteristics of its oligosaccharides upport our hypothesis of 
'brain-type' glycosylation of intrathecally synthesized cerebrospi- 
nal fluid proteins. For carbohydrate structural analysis, high-pH 
anion-exchange chromatography, methylation analysis, liquid 
secondary ion- and matrix-assisted laser desorptionl ionization 
mass spectrometry of the permethylated erivatives were used. 
The major structure turned out to be a complex-type agalacto- 
diantennary oligosaccharide with bisecting N-acetylglucosamine 
and proximal fucose. Analysis of a second transferrin preparation 
containing both asialo- and sialo-transferrin revealed another 
major glycan species derived from the sialylated transferrin var- 
iant which is galactosylated and lacks bisecting N-acetylglu- 
cosamine and fucose. 
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1. Introduction 
We have recently shown that fl-trace protein isolated from 
human cerebrospinal fluid (CSF) is modified by N-linked com- 
plex-type diantennary oligosaccharides which are characterized 
by large proportions of asialo- and agalacto-chains typically 
containing proximal fucose (Fuc) and bisecting N-acetylglu- 
cosamine (GlcNAc) [1]. As discussed previously, such gly- 
coforms cannot persist in blood due to the existence of specific 
hepatic learance mechanisms ( ee, e.g. [2]). 
In order to further substantiate our hypothesis on 'brain- 
type' glycosylation of intrathecally synthesized secretory poly- 
peptides [1 ] we have structurally characterized the N-glycans of 
CSF-transferrin. 
Human transferrin is a 79,570 Da glycoprotein with two 
N-glycosylation sites at Asn-413 and Ash-611 [3]. The protein 
isolated from human serum bears complex-type diantennary 
(85%) and triantennary (15%) oligosaccharides with ~2,6- 
linked N-acetylneuraminic a id (NeuNAc) and c~2,3-1inked 
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NeuNAc on the additional branch of the triantennary oligosac- 
charides [4-6]. As both glycosylation sites may be occupied by 
two di-, one di-and one tri- or two triantennary chains, the 
maximum number of NeuNAc-residues varies from 4-6 (82%/ 
17%/<1% of the respective glycoforms in serum [7]); only low 
amounts of asialo-and monosialo-variants have been reported 
[8]. Di- and trisialo-transferrin also constitute minor species, 
the disialoform being elevated in cases of alcoholism [3]. Sero- 
transferrin isolated from the human hepatocarcinoma cell line 
Hep G2 has been shown to contain large amounts of higher 
antennary oligosaccharides with proximal fucose as well as 
peripheral fucose [9]. Altered glycosylation ofserum transferrin 
has been reported to be associated with certain diseases [1~12] 
and has also been detected uring pregnancy [7]. 
Transferrin is also an important protein constituent of 
human CSF, some 30% being present in an unsialylated form 
[13]. This asialo-transferrin, also named flz-transferrin or 
v-globulin, can be distinguished from the sialylated variant by 
its higher mobility e.g. in agarose electrophoresis [13]. The 
origin of CSF-asialo-transferrin has not yet been conclusively 
elucidated. Suggestions include either intrathecal synthesis by 
a neuraminidase acting on serum-derived transferrin in the 
brain compartment or de-novo-synthesis of transferrin [14-17]. 
Here we present for the first time a characterization f human 
asialo- and sialotransferrin from cerebrospinal fluid providing 
evidence for local synthesis of the asialo-fraction. 
2. Experimental 
2.1. Isolation of transferrin from human cerebrospinal fluid ( CSF) 
Lumbar CSF was obtained from patients of the Neurological Clinic 
after informed consent as part of routine diagnostic procedures. For the 
analyses reported here, only non-pathological s mples were pooled. 
After 35-fold concentration using a YM 3-membrane (Amicon, Witten, 
Germany) and dialysis against 20 mM Tris-HCl (pH 8.0) a sample 
containing 40 mg protein was subjected toanion exchange chromatog- 
raphy with DEAE MemSep 1010 (Millipore, Eschborn, Germany). The 
unbound material (containing asialo-transferrin) a d the fronting part 
of a double-peak eluted with 25 mM NaC1 in 0.02 M Tris pH 8.0 
(residual asialo-transferrin a d a part of the sialo-transferrin) were 
fractionated separately by gel filtration on an AcA 54 column as de- 
scribed [18]. The transferrin-containing fractions were either pooled for 
analysis of whole CSF-transferrin oranalyzed separately in the case of 
the asialo-variant after removal of contaminating IgG by binding to 
protein A-CPG-gel (Bioprocessing, Durham, UK). 
2,2. Sodium-dodecylsulfate polyacrylamide gel electrophoresis 
Protein separation was analyzed as detailed [18] using 10% poly- 
acrylamide gels. 
Z3. Generation of tryptic glycopeptides and isolation of N-linked glycans 
Since native transferrin is not accessible to digestion with poly- 
peptide-N4-(N-acetyl-glucosaminyl)asparagine amidas  F (PNGase 
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F), tryptic digestion of the protein and separation of the peptides by 
reversed-phase HPLC on a Vydac Cis-column were performed essen- 
tially as detailed [18] using gradient elution with solvent A: 0.1% (v/v) 
trifluoroacetic acid and solvent B: 80% (v/v) acetonitrile in 0.1% tri- 
fluoroacetic acid. Glycopeptides were identified by carbohydrate com- 
positional analysis of aliquots of the HPLC-fractions. N-linked glycans 
were recovered from the pooled glycopeptide material by digestion with 
PNGase F and oligosaccharides were isolated by reversed-phase 
HPLC. 
2.4. Oligosaccharide structural nalysis 
Liberation of N-linked glycans by PNGase F, desalting of oligosac- 
charides, anion exchange chromatography of N-linked oligosac- 
charides at neutral pH on a MonoQ-column, enzymatic removal of 
neuraminic acid, and carbohydrate compositional and methylation 
analysis have been described in detail [1,19]. 
2.5. High-pH anion exchange chromatography (HPAEC) of 
oligosaccharides 
Analysis method and standard oligosaccharides were detailed previ- 
ously [1,20]. Desialylated, esalted oligosaccharides were separated by 
the following gradient (solvent A = 0.2 M NaOH, solvent B -- 0.6 M 
sodium acetate in A): after 2 min isocratic run at 100% A, a 38-min 
linear un to 90% A and then a 10-min linear un to 80% A were applied. 
After 10 min at 80% A, the gradient was completed by a 1-min run to 
0% A. 
2.6. Matrix assisted laser desorption/ ionization time of flight mass 
spectrometry ( MALDIITOF-MS) 
2,5-Dihydroxybenzoic a id was used as UV-absorbing matrix. 
10 mg/ml 2,5-dihydroxybenzoic acid were dissolved in 10% ethanol in 
water. For analysis by MALDI/TOF-MS the solutions of the reduced 
and permethylated oligosaccharides were mixed with the same volume 
of matrix. 1/.tl of the sample was spotted onto a stainless teel tip and 
dried at room temperature. The concentrations of the analyte mixtures 
were approximately 10 pmol//.tl. 
Measurements were performed on a Bruker REFLEX MALDI/TOF 
mass spectrometer using a N 2 laser (337 nm) with 3 ns pulse width and 
107 to 108 W/cm 2 irradiance at the surface (0.2 mm 2 spot). Spectra were 
recorded at an acceleration voltage of 20 kV using the reflectron for 
enhanced resolution. 
3. Results 
3.1. Isolation of N-linked oligosaccharides from CSF-transferrin 
About 100/~g of asialo-transferrin or 560/lg of a mixture of 
asialo-transferrin and sialo-transferrin were obtained from 
100 ml of pooled human CSF as described in section 2. Amino 
acid sequencing yielded the single N-terminal sequence 
VPDKTVRW thus demonstrating the purity of both protein 
preparations. 
Since oligosaccharides could not be detached by PNGase 
F-digestion from the native protein, the transferrin prepara- 
tions were subjected to reduction, carboxamidomethylation 
and tryptic digestion as described [18]. Oligosaccharides were 
then liberated enzymatically from the tryptic glycopeptides and 
were isolated in the flow-through of a second reversed-phase 
HPLC-run. 
3.2. Character&ation of transferr& glycans 
Preliminary characterization of  the oligosaccharides from 
the asialo-transferrin preparation yielded one major peak, I, 
upon HPAEC (see Fig. l a) which had an identical retention 
time as an agalacto-diantennary reference oligosaccharide with 
bisecting GlcNAc and proximal fucose which represents the 
predominant N-glycan in human fl-trace protein isolated from 
CSF (cf. Fig. lc and Table 2) [1]. MALDI -MS which yielded 
a prominent molecular ion signal at 2097 Da [Hex 3 HexNAc4 
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Fig. 1. High-pH anion-exchange profile of human CSF-transferrin oli- 
gosaccharides obtained as described in section 2. Panel a shows the 
elution profile of oligosaccharides from asialo-transferrin, (b) from 
asialo- plus sialo-transferrin, (c)of total oligosaccharides from CSF-fl- 
trace protein. 1 = NeuNAc, 2 = diantennary complex-type glycan with 
proximal fucose plus diantennary complex-type with proximal Fuc and 
bisecting GIcNAc lacking one Gal, 3 = diantennary complex-type oli- 
gosaccharide with bisecting GlcNAc and proximal Fuc (1 3 were de- 
scribed in [1]). I and II represent a diantennary complex-type glycan 
with bisecting GlcNAc and proximal Fuc lacking two Gal and a 
diantennary complex-type glycan, respectively (cf. Table 2). 
deoxyHex HexNAc-ol] + Na ÷, Fig. 2a, and methylation analy- 
sis (data not shown) confirmed this interpretation. Based on the 
monosaccharide derivatives detected, the presence of partially 
galactosylated as well as higher antennary chains and those 
lacking proximal fucose could also be inferred. Detection of 
several minor molecular ion signals as explained in the legend 
to Fig. 2 supported these findings. 
Due to the low amounts of oligosaccharide material available 
from the pure asialo-transferrin, the structural analyses were 
repeated and extended using a mixture of asialo- and sialo- 
transferrin obtained as described under Experimental. The 
total N-linked oligosaccharides from this preparation were sub- 
jected to HPAEC after desialylation (Fig. lb), MALDI -MS 
(Fig. 2b), and methylation analysis (Table 1). As shown in Fig. 
lb, HPAEC revealed two major structures, I and II, in a ratio 
of about 1 : 2 (the third peak, 1, is caused by NeuNAc liberated 
during the digestion process which was not removed prior to 
HPAEC). Peak I had the same elution time as the prominent 
peak in Fig. 1 a and thus clearly derived from asialo-transferrin 
whereas peak II eluted at a position identical with a dianten- 
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Fig. 2. MALDI-MS of the reduced and permethylated oligosaccharides 
of human transferrin isolated from cerebrospinal fluid. Panel a shows 
the complex-type oligosaccharides of CSF-asialo-transferrin, panel b 
the oligosaccharides of total CSF-transferrin. Based on the data pre- 
sented in Fig. 1 and Table 1 as well as upon liquid secondary ion mass 
spectrometry we propose the following structures to be present: (1) 1923 
Da [Hex3 HexNAc4 HexNAc-ol] + Na + is compatible with a dianten- 
nary glycan bearing bisecting GlcNAc and lacking two Gal, (2) 2097 
Da [Hex3 HexNAc 4 deoxyHex HexNAc-ol] + Na+: diantennary with 
proximal Fuc and bisecting GIcNAc lacking two Gal, (3) 2168 Da [Hex 3 
HexNAc~ HexNAc-ol] + Na+: triantennary with bisecting GlcNAc 
lacking three Gal or tetraantennary lacking four Gal, (4) 2302 Da [Hex 4 
HexNAc 4 deoxyHex HexNAc-ol] + Na+: diantennary with proximal 
Fuc and bisecting GIcNAc lacking one Gal, (5) 2343 Da [Hex 3 
HexNAcs deoxyHex HexNAc-ol] + Na+: triantennary with proximal 
Fuc and bisecting GlcNAc lacking three Gal or tetraantennary with 
proximal Fuc lacking four Gal, (6) 2447 Da [NeuNAc Hexs HexNAc3 
HexNAc-ol] + Na+: diantennary, monosialylated, (7) 2476 Da [Hex 4 
HexNAc 4 deoxyHex 2 HexNAc-ol] + Na+: diantennary with proximal 
and one peripheral Fuc and bisecting GlcNAc lacking one Gal, (8) 2620 
Da [NeuNAc Hex5 HexNAc3 deoxyHex HexNAc-ol] + Na+: bianten- 
nary with proximal Fuc, monosialylated, (9) 2721 Da [Hex 4 HexNAc 5 
deoxyHex 2 HexNAc-ol] + Na*: triantennary with two Fuc and bisect- 
ing GIcNAc lacking two Gal or tetraantennary with two Fuc lacking 
three Gal, (10) 2809 Da [NeuNAc2 Hex5 HexNAc3 HexNAc-ol] + Na+: 
diantennary, disialylated, (I 1) 2983 Da [NeuNAc2 Hex5 HexNAc3 de- 
oxyHex HexNAc-ol] + Na+: diantennary with one Fuc, disialylated. In 
addition, molecular ion signals resulting from K+-adducts of the respec- 
tive structures ([M+16] ÷) as well as from undermethylated structures 
([M-14] +) can be distinguished. 
nary complex-type standard oligosaccharide lacking proximal 
fucose and bisecting GlcNAc (cf. Table 2 and [1]) and was 
released from the sialylated transferrin variant. Corresponding 
with this interpretation, MALDI -MS analysis (Fig. 2b) of the 
reduced and permethylated oligosaccharide mixture revealed 
three predominant molecular ion signals. The signal at m/ 
z -- 2097 Da (peak no. 2:[Hex3 HexNAc4 deoxyHex HexNAc- 
ol] + Na ÷) was already seen with asialo-transferrin (cf. Fig. 2a), 
the signals at m/z = 2447 and 2809 Da (no. 6 and 10, [NeuNAc 
Hex 5 HexNAc 3 HexNAc-ol] + Na ÷ and [NeuNAc2 Hex s 
HexNAc3 HexNAc-ol] + Na ÷) are caused by diantennary com- 
plex-type glycans bearing one or two NeuNAc-residues, respec- 
tively. Minor molecular ion signals are explained in the legend 
to Fig. 2. The methylation data obtained (Table 1) further 
confirmed and expanded these results. Thus, detection of about 
0.3 mol 2-mono-O-methylmannitol argues for the presence of 
about 30% of an oligosaccharide with bisecting GlcNAc. This 
glycan also bears Fuc in a proximal position (30% 4,6-disubsti- 
tuted N-acetylglucosaminitol-derivative) but lacks terminal 
Gal-residues on both antennae (high values of non-substituted 
N-acetylglucosaminitol) as evidenced by the MS data (structure 
A, Table 2). Oligosaccharide B, the desialylated structure 
of which is shown in Table 2, constitutes about 70% of the 
total sugar material. It is completely galactosylated, bearing 
NeuNAc almost exclusively in c~2,6-1inkage (1.5 mol 6-substi- 
tuted galactose) but lacks bisecting GlcNAc (0.7 mol 3,6-disub- 
stituted mannitol) and Fuc (0.7 mol 1,3,5,6-tetra-O-methyl-N- 
acetylglucosaminitol). This glycan is identical to the major 
transferrin oligosaccharide found in human serum. 
4. Discussion 
To our knowledge, pure asialo-transferrin from human CSF 
was analyzed for the first time in this report. This transferrin 
variant turned out to contain one major type of N-linked dian- 
tennary complex-type oligosaccharides with two agalacto- 
antennae, bisecting GlcNAc and proximal fucose. Thus, the so- 
called asialo-transferrin turned out to be in fact an asialo- 
agalacto-transferrin. This oligosaccharide structure has never 
Table 1 
Methylation analysis of total CSF-transferrin oligosaccharides 
Peracetylated derivative of Transferrin Substitution i  
position 
Fucitol 
2,3,4-Tri-O-methyl- 0.3 
Galacitol 
2,3,4,6-Tetra-O-methyl- 0.3 - 
2,4,6-Tri-O-methyl- 0.1 3 
2,3,4-Tri-O-methyl- 1.5 6 
Mannitol 
3,4,6-Tri-O-methyl-* 2.0 2 
3,6-Di- O-methyl- < 0.1 2; 4 
3,4-Di-O-methyl- 0.1 2; 6 
2,4-Di-O-methyl- 0.7 3; 6 
2-Mono-O-methyl- 0.3 3; 4; 6 
2-N-Methylacetamido-2- 
deoxyglucitol 
1,3,5,6-Tetra-O-methyle- 0.7 4 
3,4,6-Tri-O-methyl- 0.8 
1,3,5-Tri-O-methylo- 0.3 4; 6 
3,6-Di-O-methyl- 2.7 4 
6-O-Methyl- 0.2 3; 4 
*Values are based on 3,4,6-tri-O-methylmannitol = 2.0. 
e, derivatives of the proximal N-acetylglucosaminitol. 
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Table 2 
Major oligosaccharide structures of CSF-transferrin (desialylated) 
167 
Proposed structure MALDI/TOF-MS peak HPAEC peak 
number (cf. Fig. 2) number 
Fuc0~ 1 
GlcNAcfll ---~ 2Mantel\ $ 
6 6 
GlcNAcfl I --~ 4Manfl 1 ---> 4GlcNAcfl 1 --* 4GlcNAc 
3 
GlcNAcfl 1 ---> 2Manc~ 1 /
Galfll --~ 4GlcNAcfll -~ 2Man, l \  
Galfll --~ 4GlcNAcfll ---~ 2Mana 1,/ 
6 
Marq31 --* 4GlcNAcfl 1 ---> 4GlcNAc 
3 
2 I 
6; 10 II 
before been reported in natural human transferrin preparations 
but has previously been identified as the major glycan constitu- 
ent of human CSF-fl-trace protein [1]. The striking structural 
characteristics of fl-trace and asialo-transferrin oligosac- 
charides, high amounts of terminal galactose and/or terminal 
GIcNAc including bisecting GIcNAc and complete proximal 
fucosylation as well as significant amounts of peripheral fuco- 
sylation, have now led us to establish the hypothesis of '  brain- 
type' glycosylation of secretory proteins produced by human 
brain tissue. These structural motifs seem to be common for 
glycoproteins synthesized by brain tissue of different mammal- 
ian species since they have also been reported for rat [21] and 
mouse [22] brain membrane glycoproteins as well as human 
myelin-associated glycoprotein and P0 [23] and ribonucleases 
from human CSF [24]. In the case of secreted glycoproteins in
human serum such structural features would lead to rapid 
clearance from the circulation due to the carbohydrate specific- 
ity of the hepatic receptor system [2] whereas in the central 
nervous ystem such a clearance mechanism is apparently not 
operating. 
The truncated oligosaccharide structures in glycoproteins 
synthesized from mammalian brain tissue presumably result 
from low levels of terminal glycosyltransferase activities 
(GlcNAcfll ~ 4:galactosyltransferase and Galfll ~ 4GIcNAc: 
sialyltransferase as well as high levels of Galfll --~ 4GIcNAc: cd 
--* 6 fucosyltransferase and GlcNAc- transferase IlI activities. 
By contrast, he degradation ofprotein-bound oligosaccharides 
within the CSF by glycosidases i highly unlikely since only 
negligible activities of e.g. fucosidase, fl-galactosidase, and neu- 
raminidase have been measured in this body fluid (M. Gaw- 
litzek et al., unpublished results, [14,25]) 
The site of biosynthesis of CSF-proteins is often unclear. 
According to Wiederkehr [26] some 20% of the CSF-protein is 
of local origin. Transferrin mRNA and/or transferrin have been 
detected in epithelial cells of the choroid plexus, oligodendro- 
cytes, and many other parts of the rat brain [15 17]. No trans- 
ferrin mRNA was detected in choroid plexus of humans and 
some selected animals [27], however, transferrin immunoreac- 
tivity has been detected in human brain cell types [28,29], and 
transferrin mRNA was detected in cultured astrocytes [30]. 
Only for a limited number of proteins present in CSF of differ- 
ent animal species has local synthesis in the central nervous 
system been conclusively demonstrated whereas others 
(amongst them albumin) could be shown to derive from serum 
only. Our results obtained for the asialo-agalacto-transferrin in 
human CSF which turned out to be 'brain-type' glycosylated 
based on the criteria described above thus clearly argue for a 
local origin of this special transferrin variant. 
The sialylated form of transferrin i human CSF which con- 
tains preponderantly c~2,6-1inked NeuNAc and lacks proximal 
fucose as well as bisecting GIcNAc is identical to the major 
glycoform present in human serum [4]. Its glycosylation fea- 
tures thus differ clearly from those of 'brain-type' N-glycosyl- 
ated polypeptides. Therefore, it is probably derived from 
plasma via transfer across the blood-brain barrier by yet uni- 
dentified mechanisms which is in accordance with the notion 
that 80% of the protein constituents of human CSF are derived 
from serum [26]. The transferrin molecule may be a useful tool 
for studying the transport of glycoproteins across the blood- 
brain barrier. This situation, intra- and extrathecal origin of 
CSF-proteins, probably holds true for many CSF-proteins 
which are not exclusively 'brain-specific' as are myelin basic 
protein, neuron-specific enolase, glial fibrillary acidic protein, 
or fl-trace. 
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